Mupirocin-Iodophor ICU Decolonization Swap Out Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03140423 |
Recruitment Status :
Completed
First Posted : May 4, 2017
Results First Posted : February 7, 2024
Last Update Posted : February 7, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens:
Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing; Arm 2 Intervention: ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing Note: that enrolled "subjects" represents 137 individual HCA Hospitals (representing ~235 ICUs) that have been randomized.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Staphylococcus Aureus | Drug: Arm 1. Routine Care (Mupirocin/CHG) Drug: Arm 2. Iodophor/CHG Decolonization | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 353323 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Non-inferiority cluster randomized controlled trial |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing |
Actual Study Start Date : | May 1, 2017 |
Actual Primary Completion Date : | November 6, 2023 |
Actual Study Completion Date : | November 6, 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Arm 1: Routine Care (Mupirocin/CHG)
ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
|
Drug: Arm 1. Routine Care (Mupirocin/CHG)
The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths. |
Active Comparator: Arm 2: Iodophor/CHG Decolonization
ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
|
Drug: Arm 2. Iodophor/CHG Decolonization
The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths. |
- Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures [ Time Frame: 18-month intervention ]Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-susceptible Staphylococcus aureus (MSSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge. NOTE: this outcome is intended for the primary manuscript.
- Number of Participants With ICU Attributable MRSA Clinical Cultures [ Time Frame: 18-month intervention ]Methicillin-resistant Staphylococcus aureus (MRSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge. NOTE: this outcome is intended for the primary manuscript.
- Number of Participants With ICU-attributable Bloodstream Infections [ Time Frame: 18-month intervention ]All-cause bloodstream infection attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge.Includes subsets of gram positive (GP), gram negative (GN) and fungal (candida) bloodstream infections, as well as key pathogens such as S. aureus (MRSA and MSSA). NOTE: this outcome is intended for the primary manuscript.
- Mupirocin & Iodophor Resistance in MRSA Isolates [ Time Frame: 18-month intervention ]Mupirocin and iodophor resistance as measured by minimum inhibitory concentration (MIC) among MRSA isolates from ICU patients between arms. NOTE: this outcome is intended for a secondary manuscript.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;
- Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs
- All patients within adult ICUs are included, including rare patients <18 years and >=12 years.
Exclusion Criteria:
- Exclusion criteria includes ICUs with an average length of stay of less than 2 days;
- HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03140423
Principal Investigator: | Richard Platt, MD, MS | Harvard Pilgrim Health Care Institute | |
Study Director: | Susan Huang, MD, MPH | University of California, Irvine |
Documents provided by Richard Platt, Harvard Pilgrim Health Care:
Publications of Results:
Responsible Party: | Richard Platt, Professor and Department Chair, Harvard Pilgrim Health Care |
ClinicalTrials.gov Identifier: | NCT03140423 |
Other Study ID Numbers: |
PH000599A |
First Posted: | May 4, 2017 Key Record Dates |
Results First Posted: | February 7, 2024 |
Last Update Posted: | February 7, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
MRSA healthcare-associated infections mupirocin iodophor resistance |
Mupirocin Anti-Bacterial Agents Anti-Infective Agents |
Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |